RxDoctor Payments DataLook up a doctor →

Edward Cullum, MD

Cardiovascular Disease · Birmingham, ALNPI 1942423108

Payments from drug & device makers

$14,315in general payments, 2019–2025

Across 754 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Abbott$1K
  • Amgen$1K
  • Johnson & Johnson$861
  • Boehringer Ingelheim$799
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$780
  • plus $7K from 44 others

What the payments were for

  • Food & beverage$14,00698%
  • Education$3092%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,315 in reported general payments places this provider in the 80th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$309,783
Medicare patients
1,019
Services billed
5,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban835$613,831
EntrestoSacubitril/Valsartan283$255,227
XareltoRivaroxaban70$83,470
Repatha SureclickEvolocumab71$45,540
Praluent PenAlirocumab37$26,117
Metoprolol Succinate749$16,271
JardianceEmpagliflozin16$12,383
MultaqDronedarone Hcl11$8,553
Potassium Chloride533$8,308
Atorvastatin Calcium531$7,709
Losartan Potassium496$6,557
Flecainide Acetate109$6,432
Diltiazem 12hr ErDiltiazem Hcl27$5,188
ClopidogrelClopidogrel Bisulfate330$4,304
Chlorthalidone222$4,197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$762$613,831835 claims
NovartisEntresto$2,142$255,227283 claims
Johnson & JohnsonXarelto$861$83,47070 claims
Boehringer IngelheimJardiance$799$12,38316 claims
Sanofi-aventis U.S. LLCMultaq$402$8,55311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →